3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
25
Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Mesothelioma, Malignant
3
Melanoma
3
Colonic Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Non-squamous Non-small Cell Lung Cancer
2
Neoplasms by Site
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma
2
Adenocarcinoma of Lung
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Interventions
Carboplatin
3
zipalertinib
2
Cisplatin
2
zimberelimab
1
sacituzumab govitecan
1
repotrectinib
1
pembrolizumab
1
durvalumab
1
alectinib
1
Pemetrexed
1
One-Lung Ventilation
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
Pemetrexed
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled